BriaCell Therapeutics Corp.

Equities

BCT

CA1079301091

Biotechnology & Medical Research

Market Closed - Toronto S.E. Other stock markets 01:29:51 01/06/2024 am IST			5-day change	1st Jan Change
2.29 ^CAD	+7.01%		+16.24%	-70.64%

30/05	BriaCell Begins Patient Enrollment in First-in-Human Study of Bria-OTS in Advanced Metastatic Breast Cancer	MT
30/05	BriaCell Therapeutics Corp. Initiates Patient Enrollment in First-In-Human Study of Bria-Ots in Advanced Metastatic Breast Cancer	CI

BriaCell Therapeutics Corp. Appoints Miguel A. Lopez-Lago as Senior Director, Research and Development

May 11, 2021 at 04:00 pm IST

BriaCell Therapeutics Corp. announced that recently appointed Miguel A. Lopez-Lago, Ph.D. as Senior Director, Research and Development. Since 2000, Dr. Lopez-Lago has been working as a cancer scientist at Memorial Sloan-Kettering Cancer Center, New York.

Latest news about BriaCell Therapeutics Corp.

BriaCell Begins Patient Enrollment in First-in-Human Study of Bria-OTS in Advanced Metastatic Breast Cancer	30/05	MT
BriaCell Therapeutics Corp. Initiates Patient Enrollment in First-In-Human Study of Bria-Ots in Advanced Metastatic Breast Cancer	30/05	CI
BriaCell Announces Clinical Supply Agreement with BeiGene for Bria-OTS First in Human Study	28/05	MT
BriaCell Therapeutics, BeiGene Partner to Test Combination of Companies' Cancer Treatments	28/05	MT
BriaCell Therapeutics Corp. Announces Clinical Supply Agreement with BeiGene, Ltd. for Bria-OTS First in Human Study	28/05	CI
Briacell Therapeutics Insider Bought Shares Worth $2,000,001, According to a Recent SEC Filing	21/05	MT
BriaCell Therapeutics Prices $5 Million Offering; Shares Tumble	15/05	MT
BriaCell Therapeutics to Present Bria-IMT Phase 2 Findings at American Society of Clinical Oncology Annual Meeting	24/04	MT
BriaCell 2024 AACR Preclinical Poster Confirms Strong Anti-Cancer Activity of Bria-OTS+? and Bria-PROS+? Clinical Candidates for Breast and Prostate Cancer	10/04	CI
BriaCell to Showcase Latest Bria-IMT Data in Poster Presentations at 2024 AACR	09/04	MT
BriaCell Therapeutics Corp. Reports Earnings Results for the Second Quarter and Six Months Ended January 31, 2024	19/03	CI
BriaCell to Present Clinical Data in CNS Metastasis and Antibody-Drug Conjugate Resistant Breast Cancer at AACR Conference	06/03	MT
BriaCell Announces Strong Clinical Data in Breast Cancer Patients	07/02	MT
BriaCell Therapeutics Corp. Announces Strong Clinical Data in Breast Cancer Patients; Reports Another Notable Responder Case	07/02	CI
Toronto Stocks Rally; Precision Drilling Rises on 4Q Profit Growth	06/02	DJ
Briacell Therapeutics Corp. Announces Lead Prostate Cancer Candidate Bria-Pros+, Initiates Gmp Manufacturing	06/02	CI
BriaCell Images Confirm Robust Anti-Tumor Activity in Patient with "Eye-Bulging" Metastatic Breast Cancer	04/01	MT
BriaCell Has Reports 71% Central Nervous System Response Rate in Advanced Breast Cancer Patients	28/12	MT
BriaCell Brief: Has Reported 71% Central Nervous System Response Rate in Advanced Breast Cancer Patients; Comes After Shares Jumped 18% on Wednesday	28/12	MT
BriaCell Therapeutics Corp. Reports 71% Central Nervous System Response Rate in Advanced Breast Cancer Patients	28/12	CI
BriaCell Therapeutics Corp. Reports Unprecedented Preliminary Survival and Clinical Benefit in Antibody-Drug Conjugate Refractory Patient Subset	20/12	CI
BriaCell Therapeutics Corp. Reports Earnings Results for the First Quarter Ended October 31, 2023	15/12	CI
BriaCell Highlights Topline Survival and Clinical Benefit Data in Advanced Metastatic Breast Cancer at Breast Cancer Symposium	06/12	MT
BriaCell Therapeutics Corp. Highlights Outstanding Topline Survival and Clinical Benefit Data in Advanced Metastatic Breast Cancer at the 2023 SABCS	06/12	CI
BriaCell Therapeutics Corp. Announces Anew Remarkable Responder in Phase 2 Study of the Bria-IMT Combination Regimen	30/11	CI

Chart BriaCell Therapeutics Corp.

Duration

Period

More charts

Company Profile

BriaCell Therapeutics Corp. is a clinical-stage biotechnology company that develops immunotherapies to transform cancer care. The Companyâs lead drug candidate, Bria-IMT, is a cell-based patented immunotherapy that stimulates a patientâs own cancer fighting cells to attack and destroy breast cancer tumors. The Company is advancing its targeted immunotherapy program by prioritizing a Phase II clinical trial with Bria-IMT in combination with an immune checkpoint inhibitor. The Company is focused on conducting a Phase I/IIa clinical trial of Bria-IMT in a combination study with Incyteâs immune PD-1 inhibitor, retifanlimab, in advanced breast cancer. The Company is also developing Bria-OTS, an off-the-shelf personalized approach to whole cell cancer immunotherapy. The Bria-OTS immunotherapy is based on a patientâs HLA-type. Its pipeline also includes Bria-Pros, Bria-Lung, Bria-Mel and sCD80, which are in development to treat various cancers.

Sector

Biotechnology & Medical Research

Calendar

02/06/2024 - American Society of Clinical Oncology Meeting - Abstract No : TPS1137

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

2.29

Average target price

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
BRIACELL THERAPEUTICS CORP.	-70.64%	3.07Cr
VERTEX PHARMACEUTICALS INCORPORATED	+11.91%	12TCr
REGENERON PHARMACEUTICALS, INC.	+11.60%	11TCr
BIONTECH SE	-4.68%	2.43TCr
ARGENX SE	-0.82%	2.2TCr
GENMAB A/S	-10.12%	1.82TCr
WUXI APPTEC CO., LTD.	-42.12%	1.64TCr
BEIGENE, LTD.	-17.47%	1.56TCr
NEUROCRINE BIOSCIENCES, INC.	+2.77%	1.36TCr
SAREPTA THERAPEUTICS, INC.	+34.58%	1.23TCr

Bio Therapeutic Drugs